Teva files for generic Adderall in USA
Shire Pharmaceuticals of the UK says that it has received a Paragraph IV Notice letter from Teva Pharmaceuticals USA advising of the filing of an Abbreviated New Drug Application for its amphetamine combination product, a generic version of Shire's attention-deficit hyperactivity disorder drug Adderall XR.
The UK firm says that Adderall XR is the lead product in its portfolio of treatments for ADHD and is protected by two patents which expire in 2018: Shire's US patent numbers 6,322,819 and 6,605,300.
Shire has previously received Paragraph IV Notice letters from Barr Laboratories, IMPAX Laboratories and Colony Pharmaceuticals relating to their ANDAs for their respective generic versions of Adderall XR, and has filed law suits in response to these.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze